Drug Profile


Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Bristol-Myers Squibb; Immunovaccine; Incyte Corporation; MedImmune; Merck AG
  • Class Amides; Antineoplastics; Imides; Oxadiazoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I/II Colorectal cancer; Glioblastoma; Head and neck cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 07 Jun 2017 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme plan a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (NCT03182894)
  • 05 Jun 2017 Updated adverse events and efficacy data from the phase I/II ECHO-204 trial in Head and Neck cancer, Malignant melanoma, Colorectal Cancer, Non small cell lung cancer, Ovarian Cancer, Lymphoma and Glioblastoma presented at the annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 05 Jun 2017 Adverse events data from the phase I/II KEYNOTE-037 study in Solid tumours presented at the 53rd Annual Meeting of the American Society for Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top